OncoGenomX AG

OncoGenomX creates an AI-enabled decision support solution (aiCDS). Beyond today’s CDS, finding the most efficacious treatments tailored for the specific tumor of an individual patient.
Breast cancer is treated with treatment combinations tested on clinical trial patients. Neither are clinical trial patients reflective of routinely seen patients. Nor are study regimens optimal for all tumors/patients despite proven superior efficacy in study patients.
By tailoring treatment regimen to the needs of tumors and patients, PredicionStar enables maximal efficacy as the rule, better treatment results and avoidance of expenditures for ineffective treatments: On average $9.5 million per year at a hospital with 200 advanced breast cancer patients.